Stay updated on Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial page.

Latest updates to the Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial page
- Check7 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and the NIH Clinical Center's status. Updated the page revision to v3.4.1, with the previous revision v3.4.0 removed.SummaryDifference0.5%

- Check14 days agoChange DetectedThe page now shows a Show glossary option and a legend for color-coded changes (green for additions, red for deletions). It also introduces the latest revision label (Revision: v3.4.0) and a minor capitalization change in 'No FEAR Act Data'.SummaryDifference0.7%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe history now shows Revision: v3.3.4 and omits Revision: v3.3.3, which affects only revision history metadata and does not alter the study's core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check50 days agoChange DetectedNew history entries were added for Contacts/Locations, Study Design, and Study Status, along with a new version (32) and Revision: v3.3.3; the entry for HHS Vulnerability Disclosure was removed.SummaryDifference0.6%

- Check79 days agoChange DetectedThe record shows Active, not recruiting. Added Contacts/Locations, Study Design, Study Status, and Recruitment Status sections, with revision v3.3.2 dated 2025-11-19.SummaryDifference0.6%

- Check86 days agoChange DetectedNotice regarding government funding lapse and operating status, previously visible on the page, has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial page.